New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim

被引:11
作者
Ghidini, Michele [1 ]
Hahne, Jens Claus [2 ,3 ]
Trevisani, Francesco [4 ]
Panni, Stefano [1 ]
Ratti, Margherita [1 ]
Toppo, Laura [1 ]
Tomasello, Gianluca [1 ]
机构
[1] Osped Cremona, ASST Cremona, Div Oncol, Dept Med, Largo Priori 1, I-26100 Cremona, Italy
[2] Inst Canc Res, Div Mol Pathol, London SW3 6JB, England
[3] Inst Canc Res, Div Mol Pathol, Sutton, Surrey, England
[4] URI, IRCCS Osped San Raffaele, Unit Urol, Div Oncol,Dept Urol, Milan, Italy
来源
THERAPEUTICS AND CLINICAL RISK MANAGEMENT | 2016年 / 12卷
关键词
G-CSF; granulocyte colony-stimulating factors; albumin; febrile neutropenia; pegfilgrastim; COLONY-STIMULATING FACTOR; CANCER-PATIENTS; G-CSF; RECEIVING CHEMOTHERAPY; FEBRILE NEUTROPENIA; ENDOTHELIAL-CELLS; PROGENITOR CELLS; GM-CSF; GRANULOCYTE; MICE;
D O I
10.2147/TCRM.S80732
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Neutropenia and febrile neutropenia are two major complications of chemotherapy. Dose reductions, delays in treatment administration, and the use of granulocyte colony-stimulating factors are equally recommended options to preserve absolute neutrophil count in case of chemotherapy regimens bringing a risk of febrile neutropenia of 20% or higher. Recombinant granulocyte colony-stimulating factors, such as filgrastim and lenograstim, have a short elimination half-life (t(1/2)) and need to be used daily, while others, like pegfilgrastim and lipegfilgrastim, are characterized by a long t(1/2) requiring only a single administration per cycle. Balugrastim is a novel long-acting recombinant granulocyte colony-stimulating factor obtained by means of a genetic fusion between recombinant human serum albumin and granulocyte colony-stimulating factor. Albumin binding increases the molecular weight and determines a high plasmatic stability leading to a t(1/2) of similar to 19 days. Balugrastim's efficacy, safety, and tolerability have been assessed in four different clinical trials involving breast cancer patients treated with doxorubicin and docetaxel. Pegfilgrastim was chosen as a comparator. Balugrastim was noninferior to pegfilgrastim with regard to the reduction of mean duration of severe neutropenia during cycle 1. Moreover, both treatments were comparable in terms of efficacy and safety profile. Balugrastim was well tolerated, with the only related adverse event being mild to moderate bone pain. The aim of this review is to summarize the currently available literature data on balugrastim.
引用
收藏
页码:1009 / 1015
页数:7
相关论文
共 37 条
  • [1] First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy
    Avisar, Noa
    Adar, Liat
    Bock, Jason
    Mueller, Udo
    Shen, David
    Barash, Steve
    Pukac, Laurie
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (05) : 929 - 939
  • [2] Recombinant Albumin-Partnering Technology: Development Of Balugrastim, a Novel Long-Acting Granulocyte Colony-Stimulating Factor
    Avisar, Noa
    Pukac, Laurie
    Adar, Liat
    Barash, Steve
    Clark, Shane
    Liu, Patrick
    Bock, Jason
    Shen, Wenyan David
    [J]. BLOOD, 2013, 122 (21)
  • [3] Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy
    Bennett, Charles L.
    Djulbegovic, Benjamin
    Norris, LeAnn B.
    Armitage, James O.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (12) : 1131 - 1139
  • [4] PHASE-I/II STUDY OF RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR IN PATIENTS RECEIVING INTENSIVE CHEMOTHERAPY FOR SMALL CELL LUNG-CANCER
    BRONCHUD, MH
    SCARFFE, JH
    THATCHER, N
    CROWTHER, D
    SOUZA, LM
    ALTON, NK
    TESTA, NG
    DEXTER, TM
    [J]. BRITISH JOURNAL OF CANCER, 1987, 56 (06) : 809 - 813
  • [5] Buchner A, 2014, United States Patent, Patent No. [US 20140271538 A1, 20140271538]
  • [6] Effects of granulocyte-colony stimulating factor on peritoneal defense mechanisms and bacterial translocation after administration of systemic chemotherapy in rats
    Cerci, Celal
    Ergin, Cagri
    Eroglu, Erol
    Agalar, Canan
    Agalar, Fatih
    Cerci, Sureyya
    Bulbul, Mahmut
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (18) : 2596 - 2599
  • [7] DUHRSEN U, 1988, LEUKEMIA, V2, P334
  • [8] DUHRSEN U, 1988, LEUKEMIA, V2, P329
  • [9] DUHRSEN U, 1988, BLOOD, V72, P2074
  • [10] A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis
    Eyles, Jo L.
    Hickey, Michael J.
    Norman, M. Ursula
    Croker, Ben A.
    Roberts, Andrew W.
    Drake, Sarah F.
    James, Will G.
    Metcalf, Donald
    Campbell, Ian K.
    Wicks, Ian P.
    [J]. BLOOD, 2008, 112 (13) : 5193 - 5201